Recent research indicates that CAV-1 is highly expressed in some NSCLC cells, and the CRISPR-Cas9 knockout of that protein’s gene can revert such cells to a radiosensitive phenotype (Fig. 4B) (Leiser et al. 2021). The gene discussed is CAV1; the disease is non-small cell lung carcinoma.